Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.

Piotr J. Bachul,Karolina Gołąb,Lindsay Basto,Steven Zangan,Jordan Pyda,Angelica Perez-Gutierrez,Peter Borek,Ling Jia Wang,Martin Tibudan,Dong-Kha V. Tran,Roi Anteby,Gabriela S Generette,Jędrzej Chrzanowski,Wojciech Fendler,Laurencia Perea,Kumar Jayant,Aaron Lucander,Celeste C. Thomas,Louis H. Philipson,J. Michael Millis,John J. Fung,Piotr Witkowski

Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.

2021

A recent randomized, multicenter trial did not show benefit of a CXCR1/2 receptor inhibitor (Reparixin) when analysis included marginal islet mass (>3,000 IEQ/kg) for allotransplantation and when i...

Keywords:

double blind
Oncology
Islet
Multicenter trial
Prospective cohort study
trial protocol
Post-hoc analysis
Chemokine receptor
Medicine
Internal medicine
Allotransplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations